| Mouse models of Alzheimer’s disease M Yokoyama, H Kobayashi, L Tatsumi, T Tomita Frontiers in Molecular Neuroscience 15, 912995, 2022 | 108 | 2022 |
| GPR120 signaling controls amyloid-β degrading activity of matrix metalloproteinases K Kikuchi, T Tatebe, Y Sudo, M Yokoyama, K Kidana, YW Chiu, S Takatori, ... Journal of Neuroscience 41 (28), 6173-6185, 2021 | 13 | 2021 |
| ADAMTS4 is involved in the production of the Alzheimer disease amyloid biomarker APP669-711 M Matsuzaki, M Yokoyama, Y Yoshizawa, N Kaneko, H Naito, ... Molecular Psychiatry 28 (4), 1802-1812, 2023 | 7 | 2023 |
| Identification of ADAMTS4 as an APP‐cleaving enzyme at 669 site in the APP669‐711 production pathway: Biomarkers (non‐neuroimaging)/Plasma/Serum/Urine biomarkers T Tomita, M Matsuzaki, N Kaneko, M Yokoyama, Y Yoshizawa, S Iwamoto, ... Alzheimer's & Dementia 16, e039194, 2020 | 2 | 2020 |
| ADAMTS4 as an enzyme cleaving at APP669 site N Kaneko, M Yokoyama, A Korenaga, S Sekiya, S Iwamoto, M Matsuzaki, ... Alzheimer's & Dementia 19, e066492, 2023 | | 2023 |
| Screening method for app cleavage activity-controlling substances of adamts4 N Kaneko, T Tomita, Y Yoshizawa, M Matsuzaki, M Yokoyama US Patent App. 17/606,289, 2022 | | 2022 |
| The APP669‐711/Aβ1‐40 ratio as a plasma biomarker specific for the brain Aβ deposition in APP/PS1 mouse N Kaneko, M Matsuzaki, M Yokoyama, A Korenaga, S Sekiya, S Iwamoto, ... Alzheimer's & Dementia 17, e051555, 2021 | | 2021 |
